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Abstract
Background: Mobile HIV screening may facilitate early HIV diagnosis. Our objective was to examine the cost-effectiveness of
adding a mobile screening unit to current medical facility-based HIV testing in Cape Town, South Africa.
Methods and Findings: We used the Cost Effectiveness of Preventing AIDS Complications International (CEPAC-I) computer
simulation model to evaluate two HIV screening strategies in Cape Town: 1) medical facility-based testing (the current
standard of care) and 2) addition of a mobile HIV-testing unit intervention in the same community. Baseline input
parameters were derived from a Cape Town-based mobile unit that tested 18,870 individuals over 2 years: prevalence of
previously undiagnosed HIV (6.6%), mean CD4 count at diagnosis (males 423/mL, females 516/mL), CD4 count-dependent
linkage to care rates (males 31%–58%, females 49%–58%), mobile unit intervention cost (includes acquisition, operation and
HIV test costs, $29.30 per negative result and $31.30 per positive result). We conducted extensive sensitivity analyses to
evaluate input uncertainty. Model outcomes included site of HIV diagnosis, life expectancy, medical costs, and the
incremental cost-effectiveness ratio (ICER) of the intervention compared to medical facility-based testing. We considered the
intervention to be ‘‘very cost-effective’’ when the ICER was less than South Africa’s annual per capita Gross Domestic
Product (GDP) ($8,200 in 2012). We projected that, with medical facility-based testing, the discounted (undiscounted) HIV-
infected population life expectancy was 132.2 (197.7) months; this increased to 140.7 (211.7) months with the addition of
the mobile unit. The ICER for the mobile unit was $2,400/year of life saved (YLS). Results were most sensitive to the
previously undiagnosed HIV prevalence, linkage to care rates, and frequency of HIV testing at medical facilities.
Conclusion: The addition of mobile HIV screening to current testing programs can improve survival and be very cost-
effective in South Africa and other resource-limited settings, and should be a priority.
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Introduction
An estimated 6 million people in South Africa are living with
HIV/AIDS, and 300,000 die annually of their disease [1]. Access
to timely and effective antiretroviral therapy (ART) can dramat-
ically reduce HIV/AIDS-related morbidity and mortality and
decrease HIV transmission [2–8]. The South African government
has committed to increase the number of people on ART by
expanding treatment initiation criteria to include CD4 counts
#350/mL [9,10]. To realize this goal, a national HIV Counseling
and Testing (HCT) campaign started in 2010 with the objective to
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test 15 million people by 2011 and continues to scale-up services to
provide annual HIV testing for everyone in South Africa in
upcoming years [11,12]. This requires novel approaches to HIV
screening, particularly in populations that are difficult to access
through conventional strategies.
HIV counseling and testing on mobile units has begun to be
implemented throughout sub-Saharan Africa and has been
targeted by the South African government as a strategy to
introduce HCT services directly into communities [12–18].
Mobile units can access first-time testers [14,15], hard-to-reach
populations (such as men [14,18] and rural populations [14–16])
and individuals at high risk for HIV infection [13,16]. In addition,
mobile units diagnose individuals with HIV at higher CD4 counts
than medical facility-based testing [18]. Our objective was to
examine the value of mobile unit HIV testing in Cape Town,
South Africa.
Methods
Analytic Overview
We use a widely-published HIV disease simulation model, the
Cost-Effectiveness of Preventing AIDS Complications Interna-
tional (CEPAC-I) model, to evaluate the clinical and economic
value of adding a mobile HIV testing unit, including point-of-care
(POC) CD4 count testing, to current medical facility-based HIV
testing in Cape Town [19–25]. We project sites of HIV diagnosis
and linkage to care, life-expectancy, 5-year survival and engage-
ment in care, and HIV-related medical care costs for a population
offered HIV testing by one of two strategies: 1) medical facility-
based HIV testing, in which outpatients undergo diagnostic testing
via a primary health care clinic’s pre-existing HCT program; or 2)
the mobile unit intervention as well as medical facility-based
testing (hereafter referred to as the mobile unit intervention), the
addition of a one-time offer of an HIV test and POC CD4 count
via a mobile testing unit for those HIV-infected. Both strategies are
simulated in the same community; undiagnosed HIV-infected
patients can also link to clinical care following presentation with an
AIDS-defining opportunistic infection (OI). Cohort characteristics
are derived from a study of patients tested in a mobile unit in Cape
Town, South Africa from March 2010–September 2011 [26].
HIV-related costs are assessed from a modified societal
perspective (excluding patient travel time and lost wages) and
are reported in 2012 US$. We report all outcomes used to inform
resource allocation decisions on a present-value basis using a 3%
discount rate [27]. Comparative value is expressed using an
incremental cost-effectiveness ratio (ICER) to compare strategies
calculated as the additional discounted cost of the mobile unit
intervention divided by its additional benefit. Guided by the
recommendations of the WHO [28], we define an intervention as
‘‘very cost-effective’’ when its ICER is less than South Africa’s
annual per capita Gross Domestic Product (GDP) ($8,200 in 2012),
and ‘‘cost-effective’’ if less than three times the South Africa
annual per capita GDP [28,29]. We conduct sensitivity analyses by
varying major input parameters to evaluate input uncertainty on
cost-effectiveness results. We also calculate the total undiscounted
HIV-related costs for the cohort over the initial 2 years to evaluate
the budgetary impact of the intervention.
The Cost-effectiveness of Preventing AIDS Complications
International (CEPAC-I) model
We use the CEPAC-I model, a validated state transition
computer model, to simulate natural history, screening, engage-
ment in care, clinical management and costs of HIV disease. We
use both the CEPAC-I Screening and Disease Models (Appendix
S1), which have been described in detail previously [21,30,31].
The Screening Model determines whether and when HIV-infected
individuals are diagnosed and link to care. Only after HIV-
infected patients are diagnosed and successfully link to care will
they be eligible for HIV treatment. The Disease Model assesses
each simulated patient’s clinical progression and treatment; patient
engagement in care is defined by whether patients are in care,
become lost to follow-up, and/or return to care.
Screening Model. We simulate HIV screening at the
population level and account for both HIV-infected and HIV-
negative individuals. HIV testing and linkage to care occur in one
of three ways: 1) following presentation with an AIDS-defining OI
(Appendix S1); 2) via the medical facility-based program; or 3) via
the mobile unit intervention. To bias the analysis in favor of
medical facility-based testing, HIV detection by the medical
facility-based program or in the setting of an acute OI is assumed
to be 100% sensitive and results in successful linkage to care. For
simulated individuals in the mobile unit intervention, we vary the
probabilities of accepting an HIV test, completing a POC CD4
count, and subsequently linking to care via the mobile unit.
Disease Model. Individuals in both screening strategies
experience the same HIV disease progression, response to
treatment, engagement with care (after initial linkage) and
mortality. In the Disease Model, all HIV-infected individuals
undergo monthly transitions between health states that depend on
CD4 count, HIV RNA, and incidence/history of acute OI
infection. Declines in CD4 count increase the risk of OIs and HIV-
related mortality. After diagnosis and linkage to care, patients
receive guideline-concordant care with CD4 count and HIV RNA
monitoring, and are eligible for prophylaxis and ART [9,32].
Those in care have a monthly probability of becoming lost to
follow-up (LTFU) both before and after they initiate ART. Those
LTFU have a probability of returning to care in the month of an
acute OI infection, and a monthly probability of return to care
after their first year lost.
Input Parameters
Baseline Cohort Characteristics. To characterize the
simulated cohort for both the medical facility and mobile unit
testing strategies, we use population and clinical data, as well as
health care utilization and cost data from a mobile testing unit
deployed in Cape Town, South Africa [26]. When data from the
mobile unit are not available, we use data from South African
studies, including the Cape Town AIDS Cohort (Table 1) [33–41].
Males and females are analyzed separately to account for
statistically significant sex-based differences in the likelihood of
accepting a mobile unit HIV test, mean CD4 count at diagnosis,
and subsequent linkage to care among individuals tested at the
mobile unit with a CD4 count .350/mL (all p,0.05). Outcomes
are weighted based on the sex distribution of people testing at the
mobile unit (44% male). Mean mobile unit POC CD4 count at
diagnosis for males is 4236236/mL and for females is 5166272/
mL. The mean medical facility-based laboratory CD4 count at
diagnosis is lower than the mean mobile unit CD4 count, at
2916203/mL for males and 3576242 for females [18,26]. The
prevalence of undiagnosed HIV among medical facility and
mobile unit testers is 6.6% [26].
Screening Characteristics. In the medical facility-based
strategy, the average HIV testing frequency is once every 5.7 years
among HIV-negative individuals and once every 4.0 years among
HIV-infected individuals (Appendix S1) [18]. Following serial
rapid HIV tests, newly diagnosed HIV-infected patients link to
care and receive a laboratory CD4 count.
Cost-Effectiveness of Mobile Unit HIV Testing
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e85197
Table 1. Summary of base case input parameters and sensitivity analyses ranges examined for an analysis of a mobile HIV testing
unit Cape Town, South Africa.
Variable Base Case Range Ref.
Baseline cohort characteristics
Male subjects (%) 44 30–80 [26]
Age, mean years (SD) 33 (13) 20–44 [26]
Prevalence of undiagnosed HIV (%) 6.6 1–30 [26]
HIV-infected patients CD4 count at diagnosis (mean cells/mL (SD))
Mobile unit testing Male* 423 (236) [26]
Female 516 (272) [26]
Medical facility-based testing{ Male 291 (203) [18,26]
Female 357 (242) [18,26]
HIV screening
Mobile unit testing characteristics (one-time HIV test and POC CD4 count offer)
HIV test acceptance probability (%) Male* 97 70–99 [26]
Female 95 70–99 [26]
Initial HIV test (Bioline HIV-1/2 3.0, Standard Diagnostics, South Korea) [57]
Test sensitivity (%) 100
Test specificity{ (%) 99
Confirmatory HIV test (Determine HIV-1/2, Abbott Laboratories, UK) [57]
Test sensitivity (%) 100
Test specificity{ (%) 100
CD4 count POC test (Alere PIMATM Analyzer, Waltham, MA, USA)
CD4 count acceptance probability (%) 91 70–99 [26]
CD4 .350 cells/mL Male* 31 20–98
Female 51 20–98
CD4 201–350 cells/mL 49 20–98
CD4 ,200 cells/mL 58 20–98
Medical facility-based program average HIV test frequency [18]{
HIV positive result Every 4.0 yrs 1–10 yrs
HIV negative result Every 5.7 yrs 1–10 yrs
Loss to follow-up and return to care
Probability of loss to follow-up [58,59]{
Pre-ART (monthly) 0.0108 0.005–0.02
On ART (monthly) Adherence .95% 0.0016
Adherence ,50% 0.0108 0.005–0.02
Probability of return to care Assumption
With acute WHO stage 3–4 disease or TB 0.50
Without WHO stage 3–4 disease or TB after first year lost (monthly) 0.01 0.005–0.02
ART treatment
Initiation at WHO stage 3–4 disease presentation, TB, or CD4 ,350/mL [9,32]
Monthly CD4 count increase on suppressive ART (cells/mL) [41]
Initial 8 weeks 67
After 8 weeks 3
HIV screening costs (2012 US$)
Mobile testing intervention (2-year) (61,000) [26]
Purchase and modification 152.0
Mobile van resale value (56.4)
Medical/counselor salaries` 216.2
Administrative salaries/maintenance1 209.8
Total 2-year mobile unit intervention costI 521.6 250–1,000
Cost-Effectiveness of Mobile Unit HIV Testing
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In the mobile unit intervention strategy, all individuals
regardless of HIV status are offered a one-time rapid HIV test.
The probability of accepting an HIV test, accepting a CD4 count,
and linking to care are varied independently, and are not 100%.
HIV test acceptance probabilities are derived from the likelihood
of HIV test acceptance among individuals who enter the Cape
Town mobile unit (males 97%, females 95%). Reactive results are
confirmed by a second HIV rapid test. At the same visit,
individuals with a positive HIV test are offered a POC CD4 count.
Successful linkage to care is defined as a clinic visit within 3
months of mobile unit testing. Linkage to care is stratified by CD4
count and accounts for poorer linkage at higher CD4 counts. For
individuals with an observed CD4 count#350/mL, linkage to care
probabilities are stratified by observed CD4 count (49%–58%).
For individuals with an observed CD4 count $350/mL, linkage to
care probabilities are stratified by sex (males 31%, females 51%)
because of significant differences noted by gender in the Cape
Town mobile unit. In both males and females, linkage to care
generally increases as observed CD4 count decreases, consistent
with the literature [26,42,43]. Both HIV-infected individuals not
diagnosed or linked via the mobile unit and HIV-negative
individuals are eligible for repeat HIV testing as per the medical
facility-based strategy throughout their lifetimes.
ART Treatment Characteristics. ART is initiated upon
diagnosis of a severe AIDS-defining OI or TB, regardless of CD4
count, or with a CD4 count #350/mL [9,44]. Depending on their
ART adherence level, patients on ART experience a reduction in
HIV RNA and a CD4 count increase. Two ART regimens are
available to individuals over the course of their lifetime [32]. In the
first 8 weeks of successful virologic suppression individuals
experience a 67/mL CD4 count increase, followed by a 3/mL
increase per month until virologic failure [41]. Individuals
experiencing virologic suppression are susceptible to treatment
failure resulting in virologic rebound and CD4 decline. Patients
are switched from 1st to 2nd line ART after treatment failure is
confirmed by an HIV RNA count showing a 10-fold increase in
HIV RNA.
Costs. The cost to receive an HIV test in the medical facility-
based program is $9.30 per negative result and $13.90 per positive
result; these costs include the initial and confirmatory HIV tests,
staff salaries and space in a voluntary counseling and testing site
[45]. Clinic-based laboratory CD4 count cost is $13.90 [35].
Costs are calculated based on the Cape Town mobile unit’s
expenditure and utilization (Table 1) [26]. We allocate the cost of
the mobile unit by dividing the total costs of acquisition, operation
and maintenance (net of resale value) over its 2-year usable life
($521,600) by the estimated 18,870 persons who could be served in
that period. This contributes an additional $27.60 to the startup
cost for patients in the mobile unit intervention cohort. Each
person also incurs medical supplies and waste disposal costs for an
initial HIV test ($1.70) and a confirmatory test for reactive results
($2.00). This results in an estimated per-person cost of $29.30 per
Table 1. Cont.
Variable Base Case Range Ref.
No. of individuals offered a test over 2-yrs 18,870 9,440–28,310
Per-person mobile unit cost (excluding HIV test costs) 27.60 13.60–54.40
Initial HIV test 1.70 0–8.50
Confirmatory HIV test 2.00
Total per-person mobile unit cost (including HIV test costs)
HIV-negative result 29.30 14.70–44.00
HIV-positive result 31.30 15.70–46.95
POC CD4 count 7.70 0–38.00
Medical facility-based HIV testing programs" [45]
HIV-positive result 13.90
HIV-negative result 9.30
Clinical care costs (2012 US$)
Co-trimoxazole prophylaxis cost (monthly) 1.40 [34]
ART regimen cost (monthly) [33]
First-line 13.30
Second-line 40.30
Laboratory CD4 count test cost 13.90 [35]
HIV RNA cost 69.50 [35]
Inpatient hospital cost, per day 315.10 [35]
Outpatient hospital cost, per visit 32.60 [35]
*Statistically significant difference between males and females.
{Parameter derived and/or calculated from reference data.
`Comprising of one nurse practitioner ($84,200), one registered nurse ($71,100), three counselors ($47,500), one educator ($1,200) and one nurse practitioner at 20%
time ($12,200).
1Made up of one driver ($27,100), one project manager ($152,300), one data capturer/administrator ($22,000), diesel ($7,500) and general maintenance ($900).
IAssumed that van could be resold after 2 years of use.
"Costs include initial and confirmatory HIV test, staff salaries, and space in a voluntary counseling and testing site.
SD: standard deviation; POC: point-of-care; ART: antiretroviral therapy; WHO: World Health Organization; TB: tuberculosis.
doi:10.1371/journal.pone.0085197.t001
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negative result and $31.30 per positive result. Diagnosed HIV-
infected individuals also receive a POC CD4 count for $7.70.
On average, the Cape Town mobile unit operated 3 days per
week, testing approximately 40 people per day, with fluctuations
due to national holidays, weather, staffing, training and other
activities. For the remaining 2 days of the work week, the mobile
unit was deployed for an incentivized HIV testing program which
is not included as part of this study. Assuming the mobile unit
operates 5 days per week, at the capacity recorded from March
2010–March 2011, we determine that it could have tested 18,870
people over a 2-year intervention period [26].
All patients, regardless of where they were diagnosed, are
subject to the same medical costs of HIV-related care. These costs
include inpatient and outpatient services, laboratory tests, and
ART regimens, for those eligible to be on ART.
Sensitivity Analyses. In sensitivity analyses, we vary multiple
input parameters within plausible ranges to evaluate the impact on
the cost-effectiveness results for mobile unit testing. Initially, we
vary each major model parameter at a time, including the
prevalence of undiagnosed HIV, mean age of testers, medical
facility-based program average per-person HIV testing frequency,
mobile unit HIV test and POC CD4 count acceptance probabil-
ities, linkage to care probabilities, intervention cost, HIV test and
POC CD4 count test costs, as well as the probability of LTFU and
return to care. We then evaluate the interaction of the most
influential parameters in multi-way sensitivity analyses.
Budget Impact Analysis. Based on widely-cited guidelines
for the conduct of budget impact analysis [46], we evaluate the
affordability of the intervention from the perspective of the
Western Cape Department of Health, the entity that would be
responsible for funding new HIV testing programs. For both
strategies, we consider the undiscounted cost of mobile unit and
medical facility-based HIV testing (including the 2-year capital
cost for the mobile unit itself), ART and prophylaxis treatment,
CD4 count and HIV RNA laboratory monitoring, and direct
HIV-related inpatient and outpatient costs for the cohort over the
first 2 years. Though costs do include inpatient and outpatient
HIV care costs for both strategies, we do not account for any
additional buildings or infrastructure that may be required to treat
additional people identified in the mobile testing intervention. We
do not take into account costs associated with lost time, lost
productivity, or non HIV-related care, since these are not incurred
by the Department of Health.
Ethics Statement. The study was approved by the University
of Cape Town Health Sciences Faculty Ethics Committee (SA),
and the Partners Health Care Human Research Committee
(Protocol 2010P002636), Boston, Massachusetts, USA.
Results
Base Case
Life expectancy and cost-effectiveness. In the medical
facility-based strategy, the discounted life expectancy was 249.9
months (or 20.8 years; undiscounted 449.7 months, or 37.5 years)
in the overall population and 132.2 months (or 11.0 years;
undiscounted 197.7 months, or 16.5 years) in the HIV-infected
population (Table 2). The addition of a mobile unit intervention
increased projected life expectancy by 0.5 months to 250.4 months
(or 20.9 years; undiscounted by 1.0 month to 450.7 months, or
37.6 years) in the overall population and by 8.5 months to 140.7
months (or 11.7 years; undiscounted by 14.0 months to 211.7
months, or 17.6 years) for HIV-infected individuals. These results
are comparable to other screening tests [47,48]. Due to their
higher CD4 count at detection, in both strategies females had a
higher life expectancy than males. With the mobile unit
intervention, females discounted life expectancy was 146.4 months
compared to 133.4 for males.
The addition of the mobile unit intervention to current medical
facility-based testing increased the discounted average per-person
lifetime costs from $3,970 to $4,070, yielding an incremental cost-
effectiveness ratio of $2,400/year of life saved (YLS) for the mobile
unit intervention compared to medical facility-based testing.
Mechanisms of linkage to care. In the medical facility-
based testing strategy, 21% of HIV-infected people died before
linking to care and 26% were linked to care after they developed a
severe AIDS-defining OI (including TB) (Figure 1). The remaining
53% were linked via medical facility-based testing. With the
addition of the mobile unit intervention, 41% of HIV-infected
people were linked to care via the mobile unit and 32% via
medical facility-based testing. As a result, fewer people died
without ever linking (12%) or after developing a severe AIDS-
defining OI (including TB) (15%).
Survival and engagement in care at five years. Five-year
survival among the HIV-infected population in the medical
facility-based testing strategy was 69% compared to 73% in the
mobile unit intervention strategy (Figure 2). The mobile unit
intervention was associated with more people on suppressive ART,
39%, compared to 35% with medical facility-based testing.
Sensitivity Analyses
One-way sensitivity analyses. In one-way sensitivity anal-
yses, we varied major input parameters independently within
plausible ranges in both strategies (see Table 1 for ranges). The
ICER for the addition of the mobile unit intervention remained
,$2,800/YLS when we varied the mobile unit HIV test and POC
CD4 count acceptance probabilities and costs, the mobile unit
purchase and operation cost as well as LTFU and return to care
(results in Appendix S1). The ICER of the mobile unit
intervention was most sensitive to variations in the prevalence of
undiagnosed HIV ($10,000/YLS when prevalence of undiagnosed
HIV ,0.5%) and linkage to care among mobile unit testers
($3,900/YLS if ,20% linkage to care). The ICER was also
sensitive to the medical facility-based program HIV testing
frequency, but remained below $3,000/YLS even when the
frequency of medical facility-based testing was once every year.
Multi-way sensitivity analyses. We used multi-way sensi-
tivity analyses to evaluate the interplay of the most important input
parameters identified in one-way sensitivity analyses: prevalence of
undiagnosed HIV, linkage to care, and the medical facility-based
testing program per-person testing frequency (Figure 3). With
medical facility-based testing every 4 years, the mobile unit ICER
remained ,36 the annual per capita South African GDP unless the
prevalence of undiagnosed HIV was below 0.5% and linkage to
care was less than 70%. Even with annual HIV testing provided by
the medical facility-based program, the addition of the mobile unit
intervention to medical facility-based testing had an ICER ,36
GDP unless the prevalence of undiagnosed HIV was below 1%.
Budget impact analysis. For the 18,870 people projected to
be evaluated by the mobile unit over 2 years (of whom 1,240 are
HIV-infected), the total undiscounted HIV-related costs over the 2
years increased by $900,000 (from $1.5 million to $2.4 million), an
increase of 67% compared to the facility-based testing strategy
(Figure 4). Roughly $300,000 of this was attributable to the
increased costs of care for the 190 additional cases identified and
linked. The other $600,000 represents the costs of the mobile
screening program.
Cost-Effectiveness of Mobile Unit HIV Testing
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Discussion
The successes of mobile units in sub-Saharan Africa demon-
strate the potential for major benefit with mobile unit HIV testing
and integrated staging by POC CD4 in South Africa and other
resource-limited settings [13,15,17,18,26]. We used data from a
Cape Town mobile HIV testing unit, as well as the costs of testing
and treatment, in a validated HIV simulation model to assess the
clinical impact, cost, cost-effectiveness and the budgetary impact of
a mobile HIV testing intervention. We found that the mobile unit
intervention would increase the discounted life expectancy of
HIV-infected individuals in a prevalent cohort in Cape Town by
8.5 months and increase the proportion that both link to care and
initiate ART. We found that, at a 5-year horizon from the start of
observation, the proportion of HIV-infected people alive in care
increased from 53% to 59% and the proportion with suppressed
viral loads increased from 35% to 39%. This increase would result
in many lives saved, particularly in a region that has a high
prevalence of HIV, such as many areas in sub-Saharan Africa.
Further, because we used different cohort parameters, this
underestimates the actual impact of the intervention by not
accounting for the substantial proportion of patients in the medical
facility intervention who died from opportunistic infections and
other AIDS-related complications prior to HIV diagnosis. Despite
start-up costs for the mobile unit totaling $152,300, the
incremental cost-effectiveness ratio of the addition of the mobile
unit was $2,400/YLS when compared to standard medical facility-
based testing alone because the prevalence of undiagnosed HIV
was so high in the population. This ICER is considerably less than
Table 2. Model outcomes and cost-effectiveness of mobile unit HIV testing in Cape Town, South Africa.
Medical facility-based
testing Mobile unit intervention
Total population
Undiscounted life expectancy (months) 449.7 450.7
Discounted life expectancy (months) 249.9 250.4
Discounted per-person costs ($) 3,970 4,070
Incremental cost-effectiveness ratio* ($/YLS) – 2,400
HIV-infected population
5-year survival (%) 69 73
Undiscounted life expectancy (months) 197.7 211.7
Discounted life expectancy (months) 132.2 140.7
Discounted per-person costs ($) 11,270 12,430
HIV RNA suppressed at 5 years (%) 35 39
*Incremental cost-effectiveness ratios ,16 South African per capita gross domestic product ($8,200) considered very cost-effective based on WHO suggestions [28].
Costs in 2012 US$. Discounted at 3% per year (see methods). YLS: years of life saved.
doi:10.1371/journal.pone.0085197.t002
Figure 1. Model-derived mechanisms of HIV linkage in Cape Town, South Africa. The charts display the proportion of HIV-infected
individuals linked to care with the medical facility-based strategy, and the mobile unit intervention strategy. HIV: human immunodeficiency virus, OI:
Opportunistic Infection.
doi:10.1371/journal.pone.0085197.g001
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the annual per capita GDP of South Africa, which we considered to
be very cost-effective [28].
The mobile unit intervention remained very cost-effective in
nearly all sensitivity analyses and was particularly robust to
changes in the mobile unit costs including intervention start-up,
operation, maintenance, and laboratory tests. The mobile unit
remained very cost-effective even if targeted to the lowest
provincial prevalence of undiagnosed HIV in South Africa
(Western Cape, 4.4% [49,50]) as long as linkage to care
probabilities were greater than 30%. These results suggest that
even in settings with a lower yield of diagnoses and fewer
individuals successfully linking to care, the benefits of the
intervention were still well worth the financial investment. In
Khayelitsha township located in greater Cape Town, the
population is approximately 500,000 and the antenatal HIV
prevalence is estimated to be as high as 31% [51]. If this area were
targeted, substantially higher numbers of people would be
identified and linked to care with mobile testing.
Mobile unit testing is likely to be added to, rather than replace,
medical facility-based HIV screening programs, which will
improve HIV detection and linkage to care. To be conservative,
we conducted an incremental analysis and considered the mobile
unit intervention in addition to facility-based testing, rather than as
a substitute for facility-based testing. Even when medical facility-
based HIV testing was as frequent as annually, the addition of
mobile unit HIV testing in this high prevalence setting remained
very cost-effective ($3,000/YLS). These results indicate that the
potential benefits from mobile screening persist even with major
improvements in medical facility-based testing, such as might be
realized with antenatal clinic testing, and underscore how a
combination of extensive medical facility-based with mobile unit
HIV testing offers the potential for immense benefit in South
Africa and elsewhere.
Mobile testing units facilitate HIV diagnosis prior to advanced
disease [18,26,42]. In this analysis, because patients in the mobile
unit are diagnosed earlier and have a higher CD4 count at
diagnosis, fewer people linked to care after the development of a
severe OI (15%) than when only medical facility-based testing was
available (26%). There are substantial individual and public health
benefits if people with HIV are diagnosed early, link to care
Figure 2. Model-derived survival and engagement in care of HIV-infected individuals in Cape Town at 5 years from the start of
observation. The bar graphs shows the proportion (out of the initial 1,240 HIV-infected population) at 5 years who are alive, diagnosed, linked to
and retained in care, are on ART, and are HIV RNA suppressed on ART. HIV: human immunodeficiency virus, RNA: ribonucleic acid, ART: antiretroviral
therapy.
doi:10.1371/journal.pone.0085197.g002
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promptly and initiate ART when eligible; these include decreased
incidence of opportunistic infections with their associated
morbidity and mortality, and fewer HIV transmissions [2–8].
Our results also showed more favorable outcomes among females
than males, due to females’ diagnosis at higher CD4 counts and
their higher linkage to care probabilities.
Figure 3. Multi-way sensitivity analyses on prevalence of HIV, linkage to care and facility-based HIV testing frequency. Prevalence of
undiagnosed HIV is varied on the horizontal axis and linkage to care on the vertical axis. Figure a) represents the base case medical facility-based
program HIV testing frequency of once every 4 years. Figure b) represents annual medical facility-based program HIV testing. Light gray represents
scenarios with an incremental cost-effectiveness ratio (ICER) ,16 South African per capita gross domestic product ($8,200), dark gray represents
scenarios with an ICER $8,200/YLS to $24,600/YLS and black represents scenarios with an ICER .$24,600/YLS. HIV: human immunodeficiency virus,
ICER: incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0085197.g003
Figure 4. Total HIV-related cohort costs over initial 2 years in facility-based and mobile intervention strategies. This represents the
total undiscounted costs for the cohort of 18,870 for HIV-related costs over the first 2 years, to be incurred by the Western Cape Department of
Health. For both strategies HIV-related costs are comprised of HIV screening, routine CD4 and HIV RNA monitoring, ART and prophylaxis, and HIV-
related inpatient and outpatient costs. Costs are61,000 USD. HIV: human immunodeficiency virus, ART: antiretroviral therapy.
doi:10.1371/journal.pone.0085197.g004
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Given the cost-effectiveness of the Cape Town mobile HIV
testing unit, as well as the successes of a variety of programs within
sub-Saharan Africa, mobile HIV testing units are clinically
effective and feasible options in many resource-limited settings
[13,15–17,52,53]. Cost-effective interventions, however, are not
necessarily inexpensive or affordable. Deploying a mobile HIV
testing unit like the Cape Town-based mobile unit requires an
upfront investment of approximately $600,000 and long-term
additional care costs of approximately $300,000 for an additional
190 HIV cases identified and linked to care at 2 years. While this
increase in cost may be too high for some resource-limited
countries, the mobile unit model is very cost-effective by
international standards and could be affordable in Cape Town
and other similarly-resourced settings, particularly those with
higher HIV prevalences. Assuming linear marginal returns to
increased investment, if participation and costs are increased 10-
fold, to account for expansion of services throughout the greater
Cape Town area, the undiscounted cost for mobile HIV screening
would be $2,766,200 per year for each of two years; this represents
8% of the Western Cape 2013–2015 Comprehensive HIV and
AIDS grant [54]. If the prevalence of undiagnosed HIV of the
Cape Town area in which the mobile unit was deployed remained
constant at 6.6%, this would result in an additional 1,900
individuals in care at 2 years. It is possible that the mobile unit
testing capacity is higher than seen in the current experience;
increased numbers tested by each unit would make testing more
cost-effective, as the start-up costs for the tester are amortized over
larger numbers of clients. Even if the capacity of the unit was half
that in the base case analysis (390 individuals tested monthly), the
mobile unit ICER remained well below the per capita South African
GDP ($3,000/YLS).
As the population in any one area is saturated with HIV testing,
we anticipate a decrease in prevalence of undiagnosed HIV
making marginal returns non-linear. A benefit, however, of mobile
testing is that the yield (e.g. new HIV diagnoses) can be assessed in
real time (e.g. on a monthly basis). As a result, regular deployment
and re-deployment of a number of mobile units can be targeted to
areas where the prevalence of new HIV diagnoses remains
sufficiently high enough to make testing cost-effective, and mobile
units could be moved to other areas with higher prevalence or
eventually phased out of service.
Is mobile unit HIV testing economically feasible in sub-Saharan
Africa? Mobile units have been deployed in urban and rural
settings in multiple countries, including South Africa, Nigeria,
Zimbabwe, Tanzania and Uganda [13,15–17,52,53]. These
mobile units have been utilized despite barriers to widespread
implementation, such as the cost of acquisition, modification,
operation and maintenance, particularly in highly resource-
constrained settings. The diversity of approaches to using mobile
units in the region demonstrates that the requirements for mobile
testing unit implementation can be flexible to the needs and
resources of health care providers and the target community. The
Cape Town mobile unit in this analysis comprises of a van and
trailer that underwent extensive modifications [26]; a different
mobile unit deployed in rural South Africa instead consists of a
truck and tents [14]. There are also variations in the workforce
employed in different settings [13,15]. While tradeoffs regarding
capacity and quality of service should also be considered, tailoring
the design and implementation of mobile units to different settings
could further reduce costs.
There are several limitations to this analysis. First, we assumed
that, with the exception of the mean CD4 count at the time of
HIV diagnosis, the cohort characteristics and HIV disease
progression were the same for the medical facility-based testing
and the mobile unit intervention groups. This may, however, miss
social and economic differences between the cohorts that could
influence patients’ ability to access and stay in care. Second, we
based the prevalence of undiagnosed HIV for both the medical
facility and mobile unit on data collected by the mobile unit.
Though this may have underestimated the undiagnosed HIV
prevalence at the medical facility as people often go to medical
facilities when sick, we performed sensitivity analyses to explore
uncertainty in this parameter. Third, we used data from multiple
studies to define the cohort and in some cases were limited by
availability of data. Although we stratified some input parameters
by sex, we did not have sex-specific data on undiagnosed HIV
prevalence, viral load, response to treatment, or AIDS-, OI- and
toxicity-related mortality. While we anticipate that having sex-
specific parameters might alter the results slightly, there is no
reason to believe they would change policy conclusions. Fourth,
we did not consider new HIV cases that would develop during the
intervention, so only prevalent cases were considered over the 2-
year period with the focus on one-time testing. Fifth, we did not
account for the monetary benefits of HIV transmissions averted as
a result of increased ART coverage with mobile HIV screening,
nor did we quantify the benefits of transmissions likely averted due
to risk reduction associated with HIV screening [55]. Lastly, we
assumed that 100% of new diagnoses linked to care from the
medical facility-based program and after presentation with an
AIDS-defining OI, while mobile unit linkage to care was
imperfect. These last three limitations all bias the analysis in favor
of medical facility-based testing and against mobile unit testing.
Therefore, our results should be interpreted as a lower-bound
estimate of the full clinical impact and economic benefits of mobile
testing.
The now well-established benefits of timely access to ART
necessitate a strong commitment to effectively diagnose HIV-
infected individuals and ensure that they link to and remain in
care. In South Africa, the National Department of Health and the
National Health Treasury have expressed the political and
financial will to create more opportunities for frequent, regular
HIV testing [10,56]. This ambitious undertaking will only be
feasible with high-yield, economically effective strategies. This
analysis suggests that mobile HIV screening is very cost-effective in
South Africa, substantially increases the life expectancy of HIV-
infected individuals, and decreases morbidity compared to medical
facility-based testing alone. While requiring up-front investment to
get these mobile units on the road, mobile testing is an investment
well worth making to achieve the combined aims of effective
diagnosis, treatment and prevention of HIV disease in many
resource-limited settings.
Supporting Information
Appendix S1 The technical appendix includes further
details on the CEPAC model, model inputs and sources,
and sensitivity analyses.
(DOCX)
Figure S1 One-way sensitivity analyses on the addition
of mobile unit HIV testing to medical facility-based
testing. This tornado diagram summarizes the results of multiple
1-way sensitivity analyses on the incremental cost-effectiveness of
the addition of mobile unit HIV testing to medical facility-based
testing in Cape Town, South Africa. The horizontal bars represent
the incremental cost-effectiveness ratio (ICER) range as a result of
variations in each single model parameter. The solid vertical line
indicates the base case ICER ($2,400/LYS). The dashed vertical
line indicates the South Africa per capita gross domestic product
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(GDP, $8,200). YLS: years of life saved; POC: point of care.
(range; base case); SOC: standard of care.
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Figure S2 Two-way sensitivity analyses on mobile unit
test acceptance and linkage to care. This diagram shows the
incremental cost-effectiveness of the addition of mobile unit HIV
testing to medical facility-based testing under conditions of varied
mobile unit test acceptance and linkage to care. Linkage to care is
varied on the vertical axis and test acceptance is on the horizontal
axis.
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